Dr. Chase on Future Treatment Landscape of Gynecologic Malignancies

Dana M. Chase, MD, FACOG
Published: Thursday, Aug 10, 2017



Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer.

It will be interesting to see if, at some point in time, that gynecologic cancers such as vulvar cancer and cervical cancer will instead be classified by their driver mutations. By doing this, patients with vulvar cancer, for example, could enroll on basket trials with patients who have other tumor types, Chase explains. This is being explored, but only in phase I studies, she adds.

Eventually, patients will undergo a biopsy for their gynecologic malignancy, and researchers will determine how it works and find a drug to target it.


Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer.

It will be interesting to see if, at some point in time, that gynecologic cancers such as vulvar cancer and cervical cancer will instead be classified by their driver mutations. By doing this, patients with vulvar cancer, for example, could enroll on basket trials with patients who have other tumor types, Chase explains. This is being explored, but only in phase I studies, she adds.

Eventually, patients will undergo a biopsy for their gynecologic malignancy, and researchers will determine how it works and find a drug to target it.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x